Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple ascending dose study of MDV1634 in Parkinson's disease
NL-OMON42429Phase 1Active, not recruiting
- Sponsor
- Medivation
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing MDV1634 with Placebo (2 arms). Primary endpoint: Safety and tolerability of MDV1634. Started Jun 2015; status: active, not recruiting.
02
Drugs
MDV1634
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON42429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42429.